Ribavirin hcv

Common Questions and Answers about Ribavirin hcv

rebetol

148588 tn?1465778809 -4.03 vs -2.04 log10 IU/mL; median HCV RNA change at Day 15: -5.51 vs -4.83 log10 IU/mL). All 5 patients who received telaprevir/peginterferon/ribavirin triple therapy attained SVR compared with 8 of 9 patients assigned to peginterferon/ribavirin control (100% vs 89%). One must recognize, however, that infection with HCV genotype 2 has the highest cure rate of all HCV genotypes when treated with peginterferon/ribavirin.
1815939 tn?1377991799 Excellent results from using ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV. (Improved SVR rates in Genotype 1a with the Ribavirin versus without the Ribavirin.
Avatar m tn The first-phase decrease in HCV RNA was similar between groups. Patients who received ribavirin had a more rapid second-phase decrease, compared with patients who did not receive ribavirin-particularly those with an adequate first-phase decrease (0.61 vs 0.35 log10 IU/mL/week; P = .018). At 12 hours, fold induction of serum IP10 was higher in patients given the combination therapy than those given peginterferon only (7.6- vs 3.8-fold; P = .
Avatar m tn Information gleaned from studies of viral kinetics suggest that a faster rate of viral decline and a longer duration of time that a patient maintains undetectable HCV RNA while receiving peginterferon/ribavirin treatment might be associated with a higher likelihood of achieving a sustained virologic response (SVR).
1066720 tn?1254994330 However, there are clinical circumstances in which a risk–benefit assessment may favor treatment, and some data suggest that certain transplant recipients will benefit from treatment with IFN monotherapy or IFN plus ribavirin combination therapy (Table 3) (71,72,102–105). For example, HCV-associated glomerulonephritides can recur after kidney transplantation and cause progressive renal dysfunction, and antiviral therapy may be needed to prevent graft loss (106,107).
1118724 tn?1357010591 Antiviral Activity in Cell Culture In the stable HCV cell culture model system (HCV replicon), ribavirin inhibited autonomous HCV RNA replication with a 50% effective concentration (EC50) value of 11-21 mcM. In the same model, PEG-IFN α-2a also inhibited HCV RNA replication, with an EC50 value of 0.1-3 ng/mL. The combination of PEG-IFN α-2a and ribavirin was more effective at inhibiting HCV RNA replication than either agent alone.
Avatar m tn No safety events in the DMC review were considered significantly different from those expected from HCV patients taking pegylated interferon and ribavirin treatment. The committee expressed no safety concerns that would preclude enrollment of the remaining 300 patients in the ongoing phase 2b study in the HCV positive genotype 1 and 4 population, and have not recommended modification of dose or duration of any RG7128 dosing regimens.
Avatar m tn sofosbuvir/velpatasvir without ribavirin (97%); sofosbuvir plus daclatasvir with ribavirin (96%); and sofosbuvir with peginterferon plus ribavirin (95%). Among patients with cirrhosis, more achieved SVR when they received sofosbuvir/velpatasvir (96%) or sofosbuvir/daclatasvir plus ribavirin (94%) for 24 weeks, and sofosbuvir/velpatasvir plus ribavirin for 12 weeks (94%). “The key finding is that sofosbuvir/velpatasvir regimens achieve the highest efficacy in HCV genotype 3.
Avatar m tn I am a HIV/HCV coinfected 52 year old female, genotype 1a, two time INF/RIBA relapser, compensated cirrhosis. My HIV is well controlled with meds. I am extremely fortunate in having secured 24 weeks of Harvoni. My question is, does anyone think adding Ribavirin for duration of treatment (24 weeks) will up my odds of SVR? I have been on the Harvoni and Ribavirin (10000mg) for a week and can only say that I feel better than I have in a long time.
Avatar n tn We compared the virologic response to 12 weeks of treatment with peginterferon alpha-2a plus ribavirin vs peginterferon alpha-2b plus ribavirin in 380 patients who were infected with HCV genotype 1 and had high viral loads.
Avatar m tn Interim Results Show High SVR Rates With Either 12 or 24 Weeks of Telaprevir Plus Peginterferon/Ribavirin in Patients With HCV Genotype 1 and IL28B CC Genotype Among patients who completed 12 weeks of triple therapy, 100% SVR12 rate among patients who continued to receive peginterferon/ribavirin through 24 weeks vs 89% SVR4 rate among patients who stopped all therapy at 12 weeks.
148588 tn?1465778809 peginterferon alfa-2b plus ribavirin for 48 weeks. Although the study design was quite complicated, the goals included an evaluation of 28 vs 48 weeks of the triple-combination regimen and a comparison of boceprevir and peginterferon alfa-2b plus low-dose ribavirin (400-1000 mg/day) vs standard-dose ribavirin (800-1400 mg/day). Another key aspect of this trial was the assessment of a 4-week peginterferon plus ribavirin lead‑in phase before the introduction of boceprevir.
Avatar f tn Summary of Key Conclusions * Dosing according to glomerular filtration rate (GFR) may be preferable to weight-based ribavirin among ribavirin-treated HCV genotype 1/4 patients with poor renal function * Poor renal function (low GFR) associated with o Lower sustained virologic response (SVR) rates o More adverse events o Possibly due to nonoptimal ribavirin dosing * GFR varied according to sex, age, and genotype but not according to weight or body mass i
Avatar m tn i am patient of HCV. and relapser to stndard interferon with ribavirin and peg interferon with ribavirin therapy. my spleen is mild enlarged and platelet count is very low.
1815939 tn?1377991799 The US Food and Drug Administration recently approved sofosbuvir for the treatment of HCV in combination with ribavirin or ribavirin and interferon, depending on the HCV genotype being treated. Daclatasvir remains an investigational agent. Overall, 211 patients enrolled in the study. Among those with genotype 1 infection, 126 were previously untreated and 41 had failed previous therapy with telaprevir or boceprevir plus peginterferon alfa-ribavirin.
Avatar f tn Management of HCV in Patients With Genotype 3 HCV Infection (From Clinical Care Options HVC website) AASLD/IDSA Guidance for Treatment-Naive or Treatment-Experienced Genotype 3 Patients Treatment options for patients with genotype 3 HCV infection include a regimen of sofosbuvir and daclatasvir, which was recently approved by the FDA specifically for the treatment of genotype 3 HCV infection, OR a regimen of Sofosbuvir and Ribavirin, with Peginterferon if possible.
Avatar m tn (2) improving the pharmacokinetics and side-effect profile of ribavirin; and (3) targeting viral enzymes required for HCV viral replication. This report discusses the most recent findings with regard to these new approaches to the treatment of HCV infection, with special focus on specifically targeted antiviral therapy for hepatitis C (STAT-C) regimens.
Avatar f tn Depends on which PI you select and how quickly you respond to trt. Following is the response guided trt for both from their websites. You should also have a biopsy to determine the status of your liver. Good luck in you selection and hope trt goes well for you.
476246 tn?1418870914 We compared the virologic response to 12 weeks of treatment with peginterferon alpha-2a plus ribavirin vs peginterferon alpha-2b plus ribavirin in 380 patients who were infected with HCV genotype 1 and had high viral loads.